Loss of Elastic Fiber Integrity and Reduction of Vascular Smooth Muscle Contraction Resulting From the Upregulated Activities of Matrix Metalloproteinase-2 and -9 in the Thoracic Aortic Aneurysm in Marfan Syndrome

Thoracic aortic aneurysm (TAA) is the life-threatening complication of Marfan syndrome (MFS), a connective tissue disorder caused by mutations in the fibrillin-1 gene. TAA is characterized by degradation of elastic fiber, suggesting the involvement of matrix metalloproteinase (MMP)-2 and -9, the activation of which is regulated by TIMP (tissue inhibitor of MMP) types 1 and 2. We hypothesized that MMP-2 and -9 were upregulated during TAA formation in Marfan syndrome, causing loss of elastic fibers and structural integrity. We studied mice, from 3 to 12 months, heterozygous for a mutant Fbn1 allele encoding a cysteine substitution in fibrillin-1 (Fbn1C1039G/+, designated as “Marfan” mice) (n=120), the most common class of mutation in Marfan syndrome. The littermates, Fbn1+/+ served as controls (n=120). In Marfan aneurysmal thoracic aorta, mRNA and protein expression of MMP-2 and -9 were detected at 3 months and peaked at 6 months of age, accompanied by severe elastic fiber fragmentation and degradation. From 3 to 9 months, the MMP-2/TIMP-2 ratio increased by 43% to 63% compared with the controls. Dilated thoracic aorta demonstrated increased elasticity but distention caused a pronounced loss of contraction, suggesting weakening of the aortic wall. Breaking stress of the aneurysmal aorta was 70% of the controls. Contraction in response to depolarization and receptor stimulation decreased in the aneurysmal thoracic aorta by 50% to 80%, but the expression of α-smooth muscle actin between the 2 strains was not significantly different. This report demonstrates the upregulation of MMP-2 and -9 during TAA formation in Marfan syndrome. The resulting elastic fiber degeneration with deterioration of the aortic contraction and mechanical properties may explain the pathogenesis of TAA.

[1]  J. Barbour,et al.  Proteinase systems and thoracic aortic aneurysm progression. , 2007, The Journal of surgical research.

[2]  D. Judge,et al.  Endothelial dysfunction and compromised eNOS/Akt signaling in the thoracic aorta during the progression of Marfan syndrome , 2007, British journal of pharmacology.

[3]  D. Judge,et al.  Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic states , 2007, Nature Medicine.

[4]  P. Robinson,et al.  Induction of Macrophage Chemotaxis by Aortic Extracts of the mgR Marfan Mouse Model and a GxxPG-Containing Fibrillin-1 Fragment , 2006, Circulation.

[5]  Jeffery A. Jones,et al.  Expression of Matrix Metalloproteinases and Endogenous Inhibitors Within Ascending Aortic Aneurysms of Patients With Marfan Syndrome , 2006, Circulation.

[6]  S. Ekker,et al.  Functional analysis of zebrafish microfibril-associated glycoprotein-1 (Magp1) in vivo reveals roles for microfibrils in vascular development and function. , 2006, Blood.

[7]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[8]  A. Vitarelli,et al.  Aortic wall mechanics in the Marfan syndrome assessed by transesophageal tissue Doppler echocardiography. , 2006, The American journal of cardiology.

[9]  Honglin Luo,et al.  Pressure distention compared with pharmacologic relaxation in vein grafting upregulates matrix metalloproteinase-2 and -9. , 2005, Journal of vascular surgery.

[10]  J. Stone,et al.  Metalloproteinase-2 and -9 in Giant Cell Arteritis: Involvement in Vascular Remodeling , 2005, Circulation.

[11]  Kevin B. Jones,et al.  Toward an Understanding of Dural Ectasia: A Light Microscopy Study in a Murine Model of Marfan Syndrome , 2005, Spine.

[12]  D. Judge,et al.  TGF-β–dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome , 2004 .

[13]  R. Khalil,et al.  Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction. , 2004, Journal of vascular surgery.

[14]  M. Stack,et al.  Differential Regulation of Membrane Type 1-Matrix Metalloproteinase Activity by ERK 1/2- and p38 MAPK-modulated Tissue Inhibitor of Metalloproteinases 2 Expression Controls Transforming Growth Factor-β1-induced Pericellular Collagenolysis* , 2004, Journal of Biological Chemistry.

[15]  Jessica Geubtner,et al.  Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. , 2004, The Journal of clinical investigation.

[16]  Y. Takanashi,et al.  Decreased Tissue Inhibitor of Metalloproteinase-2/Matrix Metalloproteinase Ratio in the Acute Phase of Aortic Dissection , 2004, Surgery Today.

[17]  P. Walker,et al.  Abnormal Extracellular Matrix Protein Transport Associated With Increased Apoptosis of Vascular Smooth Muscle Cells in Marfan Syndrome and Bicuspid Aortic Valve Thoracic Aortic Aneurysm , 2003, Circulation.

[18]  D. Arking,et al.  Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome , 2003, Nature Genetics.

[19]  Joshua D. Wythe,et al.  A critical role for elastin signaling in vascular morphogenesis and disease , 2003, Development.

[20]  Timothy C Greiner,et al.  Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. , 2002, The Journal of clinical investigation.

[21]  D. Spina,et al.  Smooth muscle cells of the media in the dilatative pathology of ascending thoracic aorta: morphology, immunoreactivity for osteopontin, matrix metalloproteinases, and their inhibitors. , 2001, Human pathology.

[22]  J. Atkinson,et al.  Aortic Wall Mechanics and Composition in a Transgenic Mouse Model of Marfan Syndrome , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[23]  W. Garner,et al.  Transforming Growth Factor-β- and Tumor Necrosis Factor-α-mediated Induction and Proteolytic Activation of MMP-9 in Human Skin* , 2001, The Journal of Biological Chemistry.

[24]  M. Hidalgo,et al.  Development of matrix metalloproteinase inhibitors in cancer therapy. , 2001, Journal of the National Cancer Institute.

[25]  H. Dietz,et al.  Phenotypic Alteration of Vascular Smooth Muscle Cells Precedes Elastolysis in a Mouse Model of Marfan Syndrome , 2001, Circulation research.

[26]  R J Schwartz,et al.  Impaired vascular contractility and blood pressure homeostasis in the smooth muscle α‐actin null mouse , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[28]  H. Dietz,et al.  Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin-1. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. E. Luna,et al.  Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome. , 1998, Circulation.

[30]  É. Allaire,et al.  Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. , 1998, The Journal of clinical investigation.

[31]  W. Pearce,et al.  Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. , 1997, Surgery.

[32]  M. Thompson,et al.  An in Vitro Model of Aneurysmal Disease: Effect of Leukocyte Infiltration and Shear Stress on MMP Production within the Arterial Wall , 1996, Annals of the New York Academy of Sciences.

[33]  P. Delvenne,et al.  Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. , 1996, Journal of vascular surgery.

[34]  N. Kouchoukos,et al.  Sensitive detection of abnormal aortic architecture in Marfan syndrome with high-frequency ultrasonic tissue characterization. , 1995, Circulation.

[35]  Motoharu Seiki,et al.  A matrix metalloproteinase expressed on the surface of invasive tumour cells , 1994, Nature.

[36]  Ada Hamosh,et al.  Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene , 1991, Nature.

[37]  R. A. Murphy,et al.  Muscle length, shortening, myoplasmic [Ca2+], and activation of arterial smooth muscle. , 1990, Circulation research.

[38]  F. Yin,et al.  Arterial hemodynamic indexes in Marfan's syndrome. , 1989, Circulation.

[39]  J. Uitto,et al.  Marfan's syndrome: structural, biochemical, and mechanical studies of the aortic media. , 1985, The Journal of laboratory and clinical medicine.

[40]  M. Mulvany,et al.  The active tension-length curve of vascular smooth muscle related to its cellular components , 1979, The Journal of general physiology.

[41]  P. Dobrin,et al.  Mechanical properties of arteries , 1978, Physiological reviews.

[42]  D. Judge,et al.  TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. , 2004, The Journal of clinical investigation.

[43]  P. Robinson,et al.  RGD-containing fibrillin-1 fragments upregulate matrix metalloproteinase expression in cell culture: A potential factor in the pathogenesis of the Marfan syndrome , 2004, Human Genetics.

[44]  D. Arking,et al.  Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. , 2003, Nature genetics.

[45]  W. Garner,et al.  Transforming growth factor-beta - and tumor necrosis factor-alpha -mediated induction and proteolytic activation of MMP-9 in human skin. , 2001, The Journal of biological chemistry.

[46]  J. Obadia,et al.  [Thoracic aortic aneurysm in Marfan syndrome]. , 1997, Archives des maladies du coeur et des vaisseaux.